Cynthia Tsai Joins Board of Certus Critical Care

Certus Critical Care, Inc. a medical device company developing an Al enabled endo-aortic catheter for the treatment of stroke, catastrophic hemorrhage, and cardiac arrest has named Cynthia Tsai to the board of directors. The board has appointed Cynthia as Certus transitions from a research and development stage to a final regulatory stage before commercialization. Ms. Tsai will work with the board of directors at Certus as well as with its leadership to engage with key opinion leaders, the medical device industry, and investors as Certus commercializes a platform of transformational catheters.

Ms. Tsai joins the Certus board with over 30 years of leadership experience in the biotechnology and medical device industry. Ms. Tsai is currently the CEO of Tana Systems, a software company and IT company which is based in India and the United States. Ms. Tsai is also the founder and former CEO of HealthExpo, the largest consumer healthcare exposition in the United States. Ms. Tsai previously spent 16 years on Wall Street as a Vice President at Merrill Lynch and at Kidder Peabody. Ms. Tsai has been a General Partner at MassTech Ventures, a multi-million-dollar equity fund focused on developing technologies in conjunction with the Massachusetts Institute of Technology. Ms. Tsai is the recipient of multiple awards related to innovation and entrepreneurship including the Harvard Business School Alumni chapter in New York's Early Stage Honor Roll Award for Entrepreneurship and the Leading Woman Entrepreneur of the World award from the Star Foundation. Ms. Tsai received her bachelor of arts from the University of Missouri in the field of Psychology.

“Cynthia's extensive expertise in health care technology commercialization and her connections throughout the US and Internationally will help Certus rapidly transition from late development phase into commercialization," Dr. Austin Johnson, President of Certus Critical Care stated. “Cynthia has vast experience as an advisor to multiple early stage companies and has strong connections within financial institutions worldwide. These make her an ideal member of the Board." 

Ms. Tsai stated that "the platform of catheters being developed by Certus has the opportunity to revolutionize the care of critically ill patients around the world. Currently, no device or medication can provide the precision blood pressure control that is offered by the Certus devices. While stroke is a primary target for early commercialization, these devices have the potential to save the lives of people suffering from hemorrhage as well as cardiac arrest. Not only will lives be saved, but together this represents a substantial market that has not been previously realized."

Certus Critical Care's novel autonomous aortic catheter has been designed specifically to address the unmet need of hemodynamic fluctuations in stroke patients. Blood pressure variations following a stroke have been shown to lead to increased risks of hemorrhagic transformations following PA administration, bleeding complications following thrombectomy, and overall worse neurologic outcomes in stroke patients who are ineligible for TPA or thrombectomy. The Certus catheter provides instantaneous blood pressure control, significantly reducing changes in blood pressure on a second to second basis while simultaneously improving perfusion to the brain. This technology also has markets in the control of blood loss from catastrophic hemorrhage and in optimizing perfusion of the heart during CPR in patients suffering from a cardiac arrest. The Certus technology is built upon over $5M of funding from the DOD and NIH to develop the scientific basis for the therapy and all technologic development to date has been achieved using non-dilutive funding. Certus is raising its initial round of investment funding at this time.